Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Real-world evidence confirms the long-term effectiveness and safety of pembrolizumab monotherapy for advanced NSCLC with PD-L1 ≥50%. Survival outcomes closely mirrored those from previous trials, supporting the generalizability of pembrolizumab's benefit across routine practice.

Authors

Institutions

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-02-05
DOI
https://doi.org/10.1245/s10434-026-19138-7
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
24.20
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Túlio Caldonazo, Lorena Escalante Romero, Victoria Trasatti Romao, Iago T C Grillo et al.
1 citations
Annals of Surgical Oncology
Cancer Immunotherapy and Biomarkers
24.20
article

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Túlio Caldonazo, Lorena Escalante Romero, Victoria Trasatti Romao, Iago T C Grillo, Felipe S. Passos, Guilherme Franceschini Machado, Paula Duarte D’ambrosio
article en
1 citations

Abstract

Real-world evidence confirms the long-term effectiveness and safety of pembrolizumab monotherapy for advanced NSCLC with PD-L1 ≥50%. Survival outcomes closely mirrored those from previous trials, supporting the generalizability of pembrolizumab's benefit across routine practice.

Annals of Surgical Oncology
AOL (United States) (US), Universidade de São Paulo (BR), Anhembi Morumbi University (BR), Cornell University (US), Universidad de Buenos Aires (AR), Ospedale San Paolo (IT), Jena University Hospital (DE), Hospital São Paulo (BR), Mater Dei Hospital (BR)
Openalex Percentile: Top 1%
Cancer Immunotherapy and Biomarkers
24.20
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis — Túlio Caldonazo, Lorena Escalante Romero, et al. · Annals of Surgical Oncology (2026) | TGRS Research Map | TGRS